Montelukast in allergic diseases beyond asthma

Allergy and Asthma Proceedings

Volumn 28, Issue 3, 2007, Pages 287-291

  Leonardi, Salvatore ^a   Marchese, Giuseppe ^a   Marseglia, Gian Luigi ^b   La Rosa, Mario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Allergic diseases; Allergic rhinitis; Atopic dermatitis; Chronic urticaria; Cysteinyl leukotriene antagonists; Montelukast; Therapy

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIHISTAMINIC AGENT; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; QUINOLINE DERIVATIVE;

ASTHMA; ATOPIC DERMATITIS; BIOSYNTHESIS; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; RHINITIS; URTICARIA;

ACETATES; ASTHMA; DERMATITIS, ATOPIC; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; HYPERSENSITIVITY; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; QUINOLINES; RHINITIS; URTICARIA;

EID: 34447249553     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.2955     Document Type: Review

References (85)

1. Feldberg W, and Kellaway CH. Liberation of histamine and formation of lysocythin like substances by cobra venom. J Physiol 94:187-191, 1938.
2. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237:1171-1176, 1987.
3. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156:737-743, 1997.
4. Lewis RA, Austen KF, and Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645-655, 1990.
5. Schleimer RP, MacGlashan DW Jr, Peters SP, et al. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 133:614-617, 1986.
6. Wenzel S, Larsen GL, Johnston K, et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 142:112-119, 1990.
7. Von Mutius E. The rising trend in asthma and allergic disease. Clin Exp Allergy 28:45-49, 1998.
8. Nathan RA, Meltzer EO, Selner JC, and Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 99:S808-S814, 1997.
9. Leynaert B, Neukirch F, Demoly P, and Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 106:S201-S205, 2000.
10. Simons FER. Allergic rhinobronchitis: The asthma-allergic rhinitis link. J Allergy Clin Immunol 104:534-540, 1999.
11. Vignola AM, Chanez P, and Bousquet J. The relationship between asthma and allergic rhinitis: Exploring the basis for a common pathophysiology. Clin Exp Allergy Rev 3:63-68, 2003.
12. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Early bronchial airflow impairment in patients with persistent allergic rhinitis and bronchial hyperreactivity Respir Med 99:1606-1612, 2005.
13. Braunstahl GJ, and Fokkens W. Nasal involvement in allergic asthma. Allergy 58:1235-1243, 2003.
14. Braunstahl GJ, Overbeek SE, Kleinjan A, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 107:469-476, 2001.
15. Bousquet J, Van Cauwenberge P, and Khaltaev N. Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact. J Allergy Clin Immunol 108(suppl 5):S147-S334, 2001.
16. Togias A. Mechanisms of nose-lung interaction. Allergy 54(suppl 57):94-105, 1999.
17. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:5773-5780, 1997.
18. Dahlen SE. Cysteinyl leukotrienes as common mediators of asthma and allergic disease. Clin Exp Allergy Rev 3:69-73, 2003.
19. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 161:S133-S136, 2000.
20. Pavord ID, Ward R, Woltmann G, et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 160:1905-1909, 1999.
21. Pulleritis T, Praks L, Skoogh BE, et al. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 159:1814-1818, 1999.
22. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000.
23. Wilson AM, Dempsey OJ, Sims EJ, and Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 31:616-624, 2001.
24. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88:592-600, 2002.
25. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: A randomized double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 32:1020-1028, 2002.
26. Pulleritis T, Praks L, Ristoja V, and Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 109:949-955, 2002.
27. Van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 90:214-222, 2003.
28. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 92:367-373, 2004.
29. Wilson A, Dempsey OJ, Sims EJ, et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 30:833-838, 2000.
30. Wilson AM, Orr LC, Coutie WJ, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 32:126-132, 2002.
31. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 87:344-349, 2001.
32. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonist in seasonal allergic rhinitis. Clin Exp Allergy 31:61-68, 2001.
33. Moinuddin R, Delineo M, Maleckar B, et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 92:73-79, 2004.
34. Ciprandi G, Tosca MA, Milanese M, et al. Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: Histamine and leukotriene antagonism. Allerg Immunol (Paris) 36:67-72, 2004.
35. Topuz B, and Ogmen GG. Montelukast as an adjuvant to mainstay therapies in patients with seasonal allergic rhinitis. Clin Exp Allergy 33:823-826, 2003.
36. Wilson AM, O'Byrne PM, and Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: A systematic review and meta-analysis. Am J Med 116:338-344, 2004.
37. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 20:1549-1558, 2004.
38. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double-dose inhaled budesonide in adult patients with asthma. Thorax 58:211-216, 2003.
39. Peters-Golden M, and Henderson WR Jr. Role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94:609-618, quiz 618-620, 669, 2005.
40. Brain SD, and Williams TJ. Leukotrienes and inflammation. Pharmacol Ther 46:57-66, 1990.
41. 4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 103:663-670, 1999.
42. 4 and histamine in human allergic skin reactions. J Clin Invest 76:650-656, 1985.
43. James JM, Kagey-Sobotka A, and Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol 91:1155-1162, 1993.
44. 4 excretion in normal and asthmatic subjects. Am Rev Respir Dis 148:1244-1251, 1993.
45. Fauler J, Neumann CH, Tsikas D, and Frölich JC. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 128:627-630, 1993.
46. 4 levels in patients with atopic dermatitis. Br J Dermatol 136:790-791, 1997.
47. 4 excretion in patients with atopic dermatitis. Br J Dermatol 144:19-23, 2001.
48. Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status. Allergy 57:732-736, 2002.
49. Eustachio N, Alessandro P, Margherita F, et al. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol 82:297-320, 2002.
50. Yanase FJ, and David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 44:89-93, 2001.
51. Capella GL, Grigerio E, and Altomare G. A randomized trial of leukotriene receptor antagonist montekulast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 11:209-213, 2001.
52. Pei AYS, Chan HHL, and Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study. Pediatr Allergy Immunol 12:154-158, 2001.
53. Carucci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 134:785-786, 1998.
54. Veien NK, Busch-Sørensen M, and Stausbøl-Grøn B. Montelukast treatment of moderate to severe atopic dermatitis in adults. A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 53:147-149, 2005.
55. Sabroe RA, and Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 133:1003-1008, 1997.
56. Champion RH. Urticaria: Then and now. Br J Dermatol 119:427-436, 1988.
57. Greaves MW. Chronic urticaria. N Engl J Med 332:1767-1772, 1995.
58. Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, E4 in patients with chronic idiopathic urticaria and oin normal subjects. J Allergy Clin Immunol 86:759-765, 1990.
59. Chu TJ, Warren MS, and Wilmington DE. Zafirlukast (Accolate) in the treatment of chronic idiopathic urticaria - A case series. J Allergy Clin Immunol 101(suppl):S155, 1998.
60. Spector S, and Tan RA. Antileukotrienes in chronic urticaria. J Allergy Clin Immunol 101:572, 1998.
61. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonist. J Allergy Clin Immunol 102:876-877, 1998.
62. Norris GJ, and Sullivan TJ. Leukotrienes and cytokines in steroid dependent urticaria. J Allergy Clin Immunol 101:128, 1998.
63. Bensch G, and Borish L. Leukotriene modifiers in chronic urticaria (letter). Ann Allergy Asthma Immunol 83:348, 1999.
64. Tedeschi A, Suli C, Lorini M, and Airaghi L. Succesful treatment of chronic urticaria. Allergy 55:1097-1098, 2000.
65. Pacor ML, Di Lorenzo G, and Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A duble-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 31:1607-1614, 2001.
66. Hani N, Hartmann K, Camper C, et al. Improvement of cold urticaria by treatment with the leukotrienes receptor antagonist montelukast (letter). Acta Derm Venereol 80:229, 2000.
67. Berkun Y, and Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 55:203-204, 2000.
68. Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 85:156-157, 2000.
69. Nettis E, Pannolino A, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 112:212-213, 2003.
70. Nettis E, Colanardi MC, Paradiso MT, and Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: A randomized, double-blind, placebo-controlled study. Clin Exp Allergy 34:1401-1407, 2004.
71. Bagenstose SE, Levin L, and Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 113:134-140, 2004.
72. Sanada S, Tanaka T, Kameyoshi Y, and Hide M. The effectiveness of montelukast for the treatment of anti-histamine resistant chronic urticaria. Arch Dermatol Res 26:1-5, 2005.
73. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 110:484-488, 2002.
74. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619-625, 2004.
75. Reimers A, Picler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 32:1763-1768, 2002.
76. Ohnishi-Inoue Y, Mitsuya K, and Horio T. Aspirin-sensitive urticaria: Provocation with leukotriene receptor antagonist. Br J Dermatol 138:483-485, 1998.
77. Kieff DA, and Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol 114:941-945, 2005.
78. Mostafa BE, Abdel Hay H, Mohammed HE, and Yamani M. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec 67:148-153, 2005.
79. Kheirandish L, Goldbart AD, and Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 117:e61-e66.
80. Goldbart AD, Goldman JL, Veling MC, and Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 172:364-370, 2005.
81. Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache 40:158-163, 2000.
82. Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: A novel treatment using Montelukast. Gut 52:181-185, 2003.
83. Daikh BE, Ryan CK, and Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 90:23-27, 2003.
84. Vanderhoof JA, Young RJ, Hanner TL, and Kettlehut B. Montelukast: Use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr 36:293-294, 2003.
85. Friesen CA, Kearns GL, Andre L, et al. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 38:343-351, 2004.